Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Telmisartan/Amlodipine FDC vs Monocomponents
NCT02259829Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2007
- Primary completion
- Nov 2007
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of telmisartan and amlodipine in hypertension (HTN) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve from 0 extrapolated to infinity up to 168 hours and Maximum measured concentration up to 168 hours. Started Sep 2007; status: completed.
02
Drugs
telmisartanamlodipine
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT02259829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02259829.